Enanta Pharmaceuticals, Inc. (ENTA) Stock Price, News, Quote & History

Enanta Pharmaceuticals Files Patent Infringement Lawsuit Against Pfizer Over Alleged Infringement Of European Patent Regarding Pfizer's Manufacture, Use, And Sale Of Paxlovid

Enanta Pharmaceuticals Announces Planned Retirement of Longstanding Chief Executive Officer Jay R. Luly, Ph.D. After 23 Years of Company Leadership

Enanta Pharmaceuticals Announces First Patient Dosed in the RESOLVE Phase 2b/3 Study of Zelicapavir, a Potential First-in-Disease Treatment for Respiratory Syncytial Virus (RSV)

A respiratory virus has no approved antiviral. Enanta has begun testing a drug in high-risk adults.

Enanta Pharmaceuticals Doses First Patient In Its RESOLVE Phase 2b/3 Clinical Trial Of Zelicapavir In Adults At High Risk Of Severe Outcomes From RSV; Topline Data Expected In 2027

ENTA: Enanta Pharmaceuticals Inc Latest Stock Price, Analysis, News and Trading Ideas

Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at IDWeek™ 2026

Enanta Pharmaceuticals To Present Data For Zelicapavir, Oral, Once-Daily, N-Protein Inhibitor In Development For Treatment Of Respiratory Syncytial Virus At IDWeek 2026

Enanta Pharmaceuticals to Participate in September Investor Conferences

Enanta Pharmaceuticals (ENTA) Stock Faces Revenue Slip And Wider Losses

Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Lags Revenue Estimates

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2026

ENANTA PHARMACEUTICALS ($ENTA) Releases Q3 2026 Earnings

ENTA Forecast — Price Target — Prediction for 2027